The miRNA-21 Problem. MicroRNAs (miRNAs) are small non-coding RNA molecules of approximately 22 nucleotides that regulate gene expression by binding to the 3'-untranslated region of target gene mRNAs, causing their degradation or translational suppression. miRNA-21 is one of the most extensively studied miRNAs in cancer and functions as an oncogene in lung cancer, where it is consistently overexpressed. Lung cancer accounts for approximately 18.7% of all cancer-related deaths globally, with 2.5 million new cases and 1.8 million deaths in 2022 alone.
How miRNA-21 is Made. The biosynthesis of miRNA-21 follows a multi-step pathway. The miRNA-21 gene on chromosome 17 is first transcribed by RNA polymerase II into primary miRNA-21. The Drosha-Dgcr8 complex cleaves this into precursor miRNA-21, which is exported to the cytoplasm by Exportin-5. The Dicer enzyme then cleaves the precursor into a mature double-stranded molecule of approximately 22 nucleotides. One strand (the guide strand) loads into the Argonaute protein to form an RNA-induced silencing complex (RISC), which binds to target gene mRNAs and silences them.
What Regulates miRNA-21 Expression. Four main mechanisms control miRNA-21 levels. DNA methylation at promoter CpG islands normally suppresses miRNA-21; hypomethylation in tumors leads to overexpression. Transcription factors such as NF-kappaB positively regulate it while peroxisome proliferator-activated receptor-gamma (PPAR-gamma) negatively regulates it. Long non-coding RNAs (lncRNAs) and circular RNAs (circRNAs) act as competitive endogenous RNA sponges that sequester miRNA-21 and reduce its activity. Finally, hypoxic tumor environments further elevate miRNA-21 expression.
The Oncogenic Target Network. miRNA-21 promotes cancer progression primarily by silencing tumor suppressor genes that would otherwise constrain cell growth. Key direct targets include PTEN (a critical brake on the PI3K/AKT survival pathway), PDCD4 (programmed cell death factor 4), RECK (a suppressor of matrix metalloproteinases), SMAD7 (a negative regulator of TGF-beta signaling), and ASPP2 (an apoptosis-promoting protein). By suppressing these protective genes, miRNA-21 creates a permissive environment for uncontrolled tumor growth.
PI3K/AKT Pathway -- The Survival Axis. The PI3K/AKT pathway is activated when miRNA-21 suppresses PTEN, the primary negative regulator of phosphatidylinositol-3,4,5-trisphosphate (PIP3). Without PTEN, AKT becomes constitutively active, driving cell survival, mTOR activation, and suppression of pro-apoptotic gene expression. This promotes tumor growth, inhibits apoptosis, and generates resistance to chemotherapy and immunotherapy. miRNA-21 also targets ASPP2, further blocking apoptosis through p53-dependent mechanisms. Inhibiting miRNA-21 restores PTEN, reverses PI3K/AKT activation, and sensitizes lung cancer cells to both radiotherapy and cisplatin.
MEK/ERK Pathway -- Proliferation and Resistance. The MEK/ERK signaling cascade (Ras/Raf/MEK/ERK) regulates cell proliferation, differentiation, migration, and drug resistance. By targeting PDCD4, miRNA-21 activates this pathway, promoting cell division. Trametinib -- an FDA-approved ERK inhibitor -- inhibits miRNA-21 expression, restores PDCD4, and reverses osimertinib resistance in NSCLC cells, demonstrating that miRNA-21 modulation can overcome targeted therapy resistance.
TGF-beta/SMAD Pathway -- Invasion and Metastasis. The TGF-beta/SMAD pathway normally regulates cell growth through inhibitory SMAD7, which provides feedback suppression of TGF-beta signaling. miRNA-21 targets and silences SMAD7, removing this brake on TGF-beta signaling. Without SMAD7 inhibition, TGF-beta drives epithelial-to-mesenchymal transition (EMT), causing cells to lose polarity and adhesion while gaining migratory and invasive capacity. This triggers expression of mesenchymal markers (Nanog, CD44, Sox2, Snail) and transforms bronchial cells toward a tumor stem cell-like phenotype.
Hippo, NF-kappaB, and STAT3 Pathways. miRNA-21 targets kidney and brain expressed protein (KIBRA) to inhibit the Hippo signaling pathway, which would otherwise suppress YAP/TAZ oncoproteins. Without Hippo inhibition, unphosphorylated YAP/TAZ enters the nucleus and drives tumor growth gene transcription. In the NF-kappaB pathway, miRNA-21 targets PTEN to activate NF-kappaB, promoting IL-6 and IL-8 production, creating a sustained inflammatory tumor microenvironment while inhibiting caspase-3 apoptosis. Through STAT3, miRNA-21 activates the JAK/STAT pathway by suppressing SOCS1 and SHP-1, promoting cancer stem cell stemness in arsenite-induced bronchial transformation.
Promoting Proliferation. miRNA-21 overexpression increases cyclin D1 and cyclin E1 expression, pushing cells through the cell cycle. Studies with anti-miRNA-21 decreased cell division cycle 2 and cyclin B1 expression, arresting cells in G2/M phase and reducing DNA replication. Overexpression of miRNA-21 increases the proportion of tumor cells in S-phase, accelerating DNA replication and cell division. miRNA-21 from hypoxic lung cancer cell-derived exosomes mediates macrophage M2 polarization and promotes lung cancer cell proliferation via interferon-regulatory factor 1 targeting.
Invasion and Metastasis. miRNA-21 promotes EMT by targeting RECK, which normally suppresses matrix metalloproteinases (MMP2, MMP9). High miRNA-21 reduces E-cadherin expression (epithelial marker) and increases N-cadherin, vimentin, and CD147 (mesenchymal and invasion markers). Lung cancer tumor spheroids enriched with miRNA-21 promote macrophage polarization and accelerate ERK/STAT3 signaling to promote brain metastasis. The combination of downregulating miRNA-21 and upregulating let-7 provides stronger inhibition of lung cancer invasion than either approach alone.
Blocking Apoptosis. miRNA-21 inhibits both intrinsic (mitochondrial) and extrinsic (death receptor) apoptosis pathways. It suppresses pro-apoptotic Bax while promoting anti-apoptotic Bcl-2 expression. Targeting ASPP2, miRNA-21 blocks p53-dependent apoptosis signals. The lncRNA CASC2 competes with miRNA-21 and promotes p53 and Bax expression, driving apoptosis -- and overexpression of miRNA-21 reverses this effect. Antisense oligonucleotide inhibitors of miRNA-21 activate caspase-3 and caspase-8, restoring apoptosis in lung cancer cells.
Promoting Angiogenesis. Rapidly growing tumors require new blood vessel formation. miRNA-21 promotes angiogenesis by indirectly elevating vascular endothelial growth factor (VEGF) through STAT3 signaling. Knocking down STAT3 reduces miRNA-21 expression, which then reduces VEGF and inhibits angiogenesis. In arsenite-induced malignant transformation of bronchial cells, miRNA-21 elevation drives VEGF expression, promoting tumor angiogenesis. When miRNA-21 is inhibited, lung cancer cells form fewer, shorter, and less connected blood vessel tubes in tube formation assays.
Chemotherapy Resistance. miRNA-21 reduces sensitivity to multiple chemotherapeutic drugs. Knocking down miRNA-21 decreased IC50 values for carboplatin and paclitaxel in A549 lung cancer cells, confirming that miRNA-21 suppression restores chemosensitivity. Extracellular vesicles carrying miRNA-21 from brain metastases promote methotrexate resistance in leptomeningeal metastasis by suppressing PTEN and PDCD4. The lncRNA CASC2 overcomes cisplatin resistance by binding miRNA-21 and restoring PTEN/PI3K/AKT pathway suppression.
Radiotherapy Resistance. miRNA-21 overexpression promotes radioresistance through multiple mechanisms. It targets PTEN and PDCD4, both of which enhance radiation sensitivity when present. The lncRNA GAS5 sponges miRNA-21, restores PTEN, and improves radiosensitivity. A pH- and H2O2-activated ribonuclease-targeting chimera that degrades miRNA-21 increased PDCD4 expression and sensitized lung cancer cells to radiation. Additionally, miRNA-21 promotes glycolysis by upregulating HIF-1alpha, which drives hypoxic radioresistance in NSCLC.
Targeted Therapy Resistance. EGFR-tyrosine kinase inhibitors (TKIs) such as gefitinib and osimertinib are cornerstones of advanced NSCLC treatment, but resistance is nearly universal. miRNA-21 promotes AKT phosphorylation, facilitating gefitinib resistance. It targets adenylosuccinate lyase (ADSL), increases purine metabolism, and drives persistent osimertinib resistance. Inhibiting miRNA-21 restores sensitivity to EGFR-TKIs by multiple mechanisms -- a promising strategy for overcoming acquired resistance in EGFR-mutated NSCLC.
Diagnostic Biomarker Potential. miRNA-21 is detectable in serum, plasma, and exosomes from lung cancer patients. Serum miRNA-21 achieved an AUC of 0.901 for lung cancer diagnosis, with expression significantly elevated in stage III and IV disease and in patients with metastasis. The combination of peripheral blood miRNA-21 and miRNA-486 identified early lung cancer in nodules with an AUC of 0.855. Plasma miRNA-21 correlates with tumor size, and extracellular vesicular miRNA-21 in pleural lavage fluid correlates with pleural infiltration. After whole-brain radiotherapy, falling miRNA-21 levels predict treatment response and longer survival in brain metastasis patients.
CRISPR/Cas9 Gene Editing. CRISPR/Cas9 technology can directly knock out the miRNA-21 gene or its regulatory elements, inhibiting lung cancer cell proliferation, migration, and colony formation, and improving sensitivity to carboplatin and paclitaxel. This approach offers precise, permanent suppression of miRNA-21 at the genomic level, unlike RNA-based approaches that require repeated dosing.
Antisense Oligonucleotides and Small Molecules. Anti-miRNA-21 antisense oligonucleotides directly bind and block miRNA-21 activity, promoting caspase-3 and caspase-8 expression and restoring apoptosis. Small-molecule inhibitors bind to the pre-miR-21 stem-loop structure at the Dicer cleavage site, disrupting the processing of precursor to mature miRNA-21. A pH/H2O2-activated ribonuclease-targeting chimera can selectively degrade miRNA-21 in acidic tumor environments without affecting other miRNAs. Natural cancer-therapeutic agents including Tanshinone IIA, cryptotanshinone, and sinomenine inhibit miRNA-21 expression and suppress lung cancer cell proliferation and invasion.
miRNA Sponges and ceRNA Strategies. lncRNAs acting as ceRNA sponges that bind and sequester miRNA-21 provide a natural strategy for inhibition. lncRNA CASC2, PLAC2, GAS5, ASBEL, Erbb4-IR, and circ-SLC7A6 have all demonstrated efficacy as miRNA-21 sponges in preclinical models. Artificially synthesizing these ceRNA molecules or delivering circular RNA sponges could provide a therapeutic approach that mimics the body's natural miRNA regulation mechanisms.
Nanoparticle Delivery Systems. Effective delivery of miRNA-21 inhibitors to tumor cells requires overcoming systemic degradation and off-target effects. QTsome lipid nanoparticles encapsulated with anti-miRNA-21 strongly inhibited miRNA-21 expression and promoted lung cancer cell erlotinib sensitivity by restoring PTEN and reducing EGFR expression. Calcium phosphate-polymer nanoparticles co-delivering anti-miRNA-21 and adriamycin produced greater cytotoxicity than adriamycin alone. Calcium phosphate co-delivery of anti-miRNA-21 and anti-miRNA-95 significantly inhibited tumor growth and improved radiation sensitivity.
State of Clinical Trials for miRNA Therapeutics. While no clinical trials specifically for miRNA-21 in lung cancer have been conducted, related miRNA therapeutics have progressed to clinical stages in other diseases. MRX34, a liposomal miRNA-34 mimic, demonstrated maximum tolerated doses but was terminated early due to severe immunotoxic reactions -- a cautionary lesson for future miRNA drug development. MesomiR-1 (miRNA-16 mimic) showed early tolerability signals in mesothelioma and NSCLC patients. RG-012, an miRNA-21 antagonist for Alport syndrome, completed a phase II trial before early termination for unspecified reasons.
Challenges for Clinical Development. Several significant obstacles must be overcome before miRNA-21 inhibitors can be used clinically in lung cancer. In vivo specificity is challenging because each miRNA has multiple target genes -- therapeutic effects must be distinguished from off-target consequences. Chemical instability of RNA-based therapeutics requires protective formulations. Immunotoxicity as seen with MRX34 requires careful dose finding and immune monitoring. Tumor delivery remains a major barrier, as systemic administration must achieve sufficient intracellular concentrations in tumor tissue.
Combination Strategy Potential. The review identifies combination therapy as the most promising near-term application. Combining miRNA-21 inhibitors with cisplatin, carboplatin, paclitaxel, gemcitabine, erlotinib, or radiotherapy amplifies the efficacy of each modality by restoring tumor suppressor pathways that miRNA-21 had silenced. Simultaneously targeting miRNA-21 and upregulating tumor-suppressive miRNAs like let-7 provides additive inhibitory effects on lung cancer invasion. This combination approach is more likely to succeed than monotherapy given the redundancy of cancer survival mechanisms.
The Path Forward. miRNA-21 represents a compelling therapeutic target in lung cancer because it simultaneously drives proliferation, invasion, apoptosis resistance, angiogenesis, and treatment resistance through six major signaling pathways. It is detectable as a liquid biopsy biomarker with strong diagnostic accuracy. Future work should focus on improving the specificity and safety of delivery systems, validating miRNA-21 inhibitors in combination with standard-of-care therapies in animal models, and eventually translating these findings into clinical trials for NSCLC patients.